Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0022568 (keratitis)
 5,133 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The modes of action of IDU and TFT were compared in tests employing them both as a monotherapy and in combination with iodine debridement in 60 patients suffering from superficial herpetic keratitis. The combination therapy was used for patients showing only dendritic stains in the corneal epithelium, while the monotherapy was used for patients who had additional lesions in the region of Bowman's membrane. Both with the monotherapies and the combination therapies the average duration of healing was shorter with TFT.
 ...
PMID:[Clinical experience with different methods of treating herpes corneae (author's transl)]. 677 29

BVDU [(E)-5-(2-bromovinyl)-2'-deoxyuridine] has a potent and selective activity against herpes simplex (type 1) in both cell culture systems and animal models. The efficacy of topical BVDU treatment (0.1% eye drops) has been evaluated in 37 patients with different forms of herpes simplex keratitis. Of these patients, 35 were followed for 2-9 months (average 6.5 months). Most of the patients had first been treated with topical IDU (idoxuridine) or ara-A (adenine arabinoside), albeit unsuccessfully, before BVDU treatment was started. Upon BVDU treatment, dendritic corneal ulcers healed in 7.8 days (on average) and the geographic corneal ulcers in 10.8 days. BVDU also exerted a pronounced healing effect on stromal keratitis, whether it was used alone or in combination with topical corticosteroids. No early recurrences were observed. Late recurrences were seen in four patients who again responded quickly to BVDU treatment. No toxic side effects, whether local or systemic, were noted in any of the patients treated with BVDU. These results establish the efficacy of BVDU in the local treatment of herpetic keratitis in man.
 ...
PMID:Efficacy of (E)-5-(2-bromovinyl)-2'-deoxyuridine in the topical treatment of herpes simplex keratitis. 702 Apr 69

A series of 38 children with ocular herpes simplex infection is reported. The follow-up periods ranged between 1 and 10 years after the first ocular herpetic involvement. The primary ocular infection occurred in most cases between 2 and 6 years of age, with a similar rate in males and females. The number of recurrences increased with the duration of the follow-up period: during the first 2 years, recurrences developed in 50% of cases and after 2 years, all the children had new herpetic ocular attacks. Idoxuridine treatment failures were found in 11 cases of herpetic superficial keratitis. Ocular herpes simplex in children is a major cause of visual loss and disability. After a follow-up period of 5 years, 75% of patients with herpetic keratitis had a visual acuity of 5/10 or less.
 ...
PMID:[Ocular herpes simplex in children (author's transl)]. 705 36

Antiherpetic activity of a new antiviral agent, Acyclovir (ACV), was compared with that of Idoxuridine (IDU) in the treatment of keratitis induced in rabbits by type I herpes simplex virus (HSV). After topical application for 5 days, both compounds were well tolerated, but ACV was significantly more effective than IDU. Virological tests demonstrated that virus multiplication continued for a shorter period in eyes treated with ACV than in those of controls, or of animals treated with IDU, but early viral regrowth was possible. Using two HSV markers, seroneutralization and thermal sensitivity of cell culture development, variations were observed in a rabbit treated with IDU and in a control animal also. Epithetial regeneration after treatment was assessed by optical microscopy and by scanning and transmission electron microscopy. Epithelial scarring was observed to be almost complete in rabbits treated with IDU. The correlation between therapeutic, virological, and histological results in positive evidence for the use of ACV in HSV-induced ocular lesions.
 ...
PMID:[Comparison of therapeutic activity of idoxuridine and acyclovir in experimentally-induced herpetic keratitis in rabbits (author's transl)]. 721 23

IDU (5-iodo-2'-deoxyuridine), BVDU [(E)-5-(2-bromovinyl)-2'-deoxyuridine] and placebo ointments were studied for their effects on experimental herpes simplex (type 1) keratoconjuncitivitis in rabbits. When treatment was begun 65 h after virus inoculation, both BVDU and IDU prevented development of keratitis. Both BVDU and IDU were also effective in suppressing the severity of conjunctivitis, and in this respect, BVDU proved significantly better than IDU. When treatment was started 110 h after virus inoculation, BVDU proved significantly better than IDU in promoting healing of established keratitis.
 ...
PMID:(E)-5-(2-bromovinyl)-2'-Deoxyuridine in the treatment of experimental herpes simplex keratitis. 735 51

We treated a number of 141 patients suffering of herpetic keratitis--34 were treated with Acyclovir in the first 72 hours the symptoms started, 42 were treated with Acyclovir after this interval and 65 were treated with IDU. We compared visual acuity after six month and we proved that those that were treated with Acyclovir had the same or better visual performances in most cases. Recurrence rate was 0% in the first year and 2.94% in the second year for those witch were treated with Acyclovir in the first 72 hours symptoms started and 2.94% in the first year and 14.71% in the second year for those treated with Acyclovir after this interval. Patients treated with IDU had suffered 23.53% recurrences in the first year and 41.18% recurrences in the second year. Acyclovir treatment and its precociousness protect patients sight and reduce number of recurrences.
 ...
PMID:[Acyclovir treatment--its effect on visual acuity and the rate of recurrences in herpetic keratitis]. 993 53

Previous experiments demonstrated the efficiency of 0.007% para-aminobenzoic acid (PABA) in the treatment of dendriform herpetic keratitis in rabbits and showed the interferonogenic activity of local administration of PABA in this concentration in ocular tissues. A new drug Aktipol based on 0.007% PABA was developed for the treatment of viral diseases of the eyes. The drug was used in the treatment of patients with surface herpetic keratitis. It was instilled into the conjunctival sac (2 drops 8-10 times a day) or instillations were combined with subconjunctival, parabulbar injections 1-3 times a week, depending on the disease severity and course. Clinical studies demonstrated that Aktipol is effective in the treatment of surface forms of herpetic keratitis (118 patients). Cure was attained in 89.8% patients in 11.3 +/- 0.6 days. Aktipol is superior to IDU (cure in 70.6% patients) and is comparable to that of acyclovir (87.7%). Aktipol accelerates ulcer healing, resorption of infiltration, and cure by 4-5 days in comparison with IDU and is comparable to acyclovir. Aktipol is better tolerated than antiviral IDU agents and acyclovir ointment.
 ...
PMID:[The new interferon inducer Aktipol in the treatment of herpetic keratitis]. 1105 16


<< Previous 1 2 3